

NYRx the Medicaid Pharmacy Program

Growth Hormone – Adult (18 Years and Older) Prior Authorization Worksheet

Fax Number: 1-800-268-2990

Processing may be delayed if information submitted is illegible or incomplete. This form must be completed by the prescriber, not their authorized agent.

ENROLLEE INFORMATION	
Enrollee's Last Name:	Enrollee's First Name:
Date of Birth:	Enrollee's Medicaid ID (2 letters, 5 numbers, 1 letter):
PRESCRIBER INFORMATION	
Prescriber's Last Name:	Prescriber's First Name:
National Provider Identifier (NPI) Number:	
Prescriber's Street Address:	
City:	State: Zip Code
Prescriber's Phone Number:	Prescriber's Fax Number:
REQUESTED DRUG INFORMATION	
Drug Name:	Drug Strength:
Quantity:	Refills:
Directions:	
	O, date therapy was initiated:

Revision Date: 1/09/2023

Enrollee's Last Name:	Enrollee's First Name:
CLINICAL CRITERIA	
Please answer questions 1 through 4 if requesting a and non-preferred drugs can be found at https://newhormone , please continue to question 5.	a non-preferred growth hormone (a listing of preferred wyork.fhsc.com/). If requesting a preferred growth
 Has the patient has experienced a treatment fail Yes No 	ure with a preferred growth hormone?
 Has the patient has experienced an adverse drug Yes No 	reaction with a preferred growth hormone?
3. Does the patient have a documented history of s hormone and transition to a preferred growth hoYes No	successful therapeutic control with a non-preferred growth ormone is medically contraindicated?
4. Other – What is the clinical reason the patient is	unable to use a preferred growth hormone?
5. What is the diagnosis documented in the patientAdult with child-onset growth hormone deficShort bowel syndrome	c's chart that requires treatment with growth hormone? iency Adult-onset growth hormone deficiency Other:
Provide the clinical rationale for requesting grow (Note : Documentation of the original diagnosis N	rth hormone for a diagnosis that is not FDA approved MUST be included with this fax form):
For Diagnoses of Growth Hormone Deficiency:	
response to a growth hormone stimulation test? Yes No	
Please explain and include chart documentation:	

Enrollee's Last Name:	Enrollee's First Name:
CLINICAL CRITERIA (CONTINUEL	
7. Does the patient have multiple radiation therapy, or trauma? Yes No Please explain and include char	tuitary hormone deficiencies secondary to organic disease, surgery,
Acute critical illness Active malignancy Diabetic retinopathy	following contraindications (check all that apply)? Obesity with upper airway obstruction Sleep apnea or severe respiratory impairment Acute respiratory failure
 Whoever knowingly distributes, or other than the treatment of a dise the Secretary of Health and Huma offense punishable by not more the secretary of Health and Huma offense punishable by not more than 10 (2) Whoever commits any offense set is punishable by not more than 10 (3) Any conviction for a violation of particular Controlled Substances Act [21 U.S.C. 853]. As used in this subsection the term of them. 	of the Federal Food, Drug, and Cosmetic act states that ssesses with intent to distribute, human growth hormone for any use in human eror other recognized medical condition, where such use has been authorized be ervices under section 355 and pursuant to the order of a physician, is guilty of a 5 years in prison, such fines as are authorized by title 18, or both. It in paragraph (1) and such offense involves an individual under 18 years of against imprisonment, such fines as are authorized by title 18, or both. It is graphs (1) and (2) of this subsection shall be considered a felony violation of the seq.] for the purposes of forfeiture under section 413 of such Act [2] uman growth hormone" means somatrem, somatropin, or an analogue of either its authorized to investigate offenses punishable by this subsection.
	Date cally necessary for this patient and that all the information on this form . I attest that documentation of the above diagnosis and medical necessis New York Medicaid.
Fax Number: 1-800-268-2990 Prior Authorization Call Line: 1-87 Billing Questions: 1-800-343-9000	

1-877-309-9493.

For clinical questions or Clinical Drug Review Program questions, please visit http://newyork.fhsc.com or call